CB-1158 combines with immune checkpoint blockade, T cell transfer, or NK cell transfer to inhibit tumor growth. a CB-1158 in combination with PD-L1 blockade inhibited tumor growth in the CT26 model. Growth curves (left and center) and survival curves (right) are shown.
N = 10 per group. b CB-1158 combined with CTLA-4 and PD-1 blockade to inhibit tumor growth and lung metastases in the 4T1 tumor model. N = 10 per group. c CB-1158 and adoptive T cell transfer inhibited tumor growth in the B16 model. Non-myeloablative chemotherapy regimen of cyclophosphamide plus fludarabine (C/F) was administered to all groups, and IL-2 was dosed to groups receiving T cells. On study day 9, Pmel-1 T cells were transferred to mice in the T cell groups (ACT). N = 10 per group. d CB-1158 and adoptive NK cell transfer reduced lung metastases in the CT26 model. N = 6 control; N = 7 CB-1158; N = 5 NK cells; N = 5 CB-1158 + NK cells. (T test: **** P < 0.0001; *** P < 0.001; ** P < 0.01; * P < 0.05)